Recent Transactions

Advising Pharmanovia, a UK based global lifecycle management healthcare company, on the acquisition of a global central nervous system portfolio from Sanofi, the France based innovative global healthcare company

Advising Marley Spoon SE, an ASX listed global subscription-based meal kit provider, on its business combination agreement with 468 SPAC II, simultaneous capital raising and amendment to existing debt facilities

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO

Advising Stumpf Capital and Georg Stumpf on the sale of a minority interest in its wholly-owned company, Exyte, a global leader in the design, engineering and delivery of high-tech facilities, to funds affiliated with BDT Capital Partners

Facilitated the sale of KKR’s portfolio company Minnesota Rubber and Plastics, a leading provider of materials science-based elastomer and thermoplastic solutions, to Trelleborg

Advising DigitalBridge, one of the largest global digital infrastructure investors, on the sale of Wildstone, Europe’s largest owner of independent outdoor media infrastructure, to Antin Infrastructure Partners

Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise

Advised Akorn Pharmaceuticals, a specialty pharmaceuticals manufacturer and marketer, on the divestiture of its portfolio of branded ophthalmic products to Laboratoires Théa SAS

Advising Pet Circle, Australia’s leading online specialty pet company, on its unicorn Series C funding round, which included a A$125m primary capital raise

Advised MetalX, Inc., a leading ferrous and non-ferrous metal scrap recycling company, on the sale of substantially all of its ferrous scrap processing business to BlueScope Steel Limited, an Australian-listed provider of steel materials, products, systems and technologies

Advised Intega Group, an ASX-listed testing, inspection and certification buisness operating primarily in Australia and the US, on its strategic review, culminating in a cash sale to Kiwa N.V via scheme of arrangement

Advised Antin Infrastructure Partners on its acquisition of Pulsant from Oak Hill and Scottish Equity Partners. Pulsant is a hybrid cloud specialist, with a nationwide network of 10 data centres across the UK delivering secure, scalable and resilient cloud, colocation and networking services

Advising Deltalab, a leading Spanish laboratory solutions provider with dedicated manufacturing capacity, on the sale of the company to SCG Packaging Public Company Limited, the largest integrated packaging and paper company in Southeast Asia

Advised ASX-listed real estate investment trust Dexus and its unlisted diversified property fund, Dexus Wholesale Property Fund, on Dexus Wholesale Property Fund’s merger with AMP Capital Diversified Property Fund

Advised AMP Capital on the sale of its portfolio company Axión Group, a leading independent broadcasting and telecommunications infrastructure provider in Spain, to Asterion Industrial Partners, a Spanish infrastructure fund

Advised VX Fiber, an international infrastructure and technology business focused on Fibre-to-the-Home networks, on its sale to the infrastructure fund AMP Capital

Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs  

Advised Eppendorf AG, a leading family-owned life science company, on the acquisition of the centrifuge and processing equipment business of KKR-owned Koki Holdings Co., Ltd., a manufacturer of power tools and centrifuge and processing equipment 

Advised Renewi plc, a leading waste to product company, on the sale of its Canadian operations to Convent Capital, an Amsterdam-based investment firm

Advised Starpharma Holdings Limited on a US licensing agreement of its patented VivaGel BV® product with ITF Pharma, a US subsidiary of Italfarmaco S.p.A., a privately held European specialty pharmaceutical company

Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities

Advised Oak Hill Advisors in the sale of Greenpark Aparcamientos, a leading off-street car park operator, to Parkia, a portfolio company of First State Investments

Advised EQT, a leading alternative investments firm with more than EUR 37 billion of AUM on the sale of its portfolio company IslaLink, a leading neutral and independent submarine fiber infrastructure operator in the Balearic Islands

Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab

Advised Jaybro, a leading supplier of consumables to infrastructure contractors, on its sale to CHAMP Private Equity

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).

Advised Patties Foods Ltd (ASX:PFL), the leading Australian branded frozen food Company, with market leadership in the frozen savoury and frozen dessert segments, on its proposed sale to Pacific Equity Partners via Scheme of Arrangement

Advised Antin Infrastructure Partners on its sale of Antin Solar Investments, a leading Italian solar platform, to a consortium of investors comprised of Swiss Life Asset Management and Quercus Investment Partners

Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments

Advised 3i on the sale of Azelis Group, a leading pan-European distributor of specialty chemicals with an emerging presence in Asia, to funds advised by Apax partners

Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.

Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases

Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.

Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc

Advised Capvis, one of the leading buyout firms in Switzerland and one of the main mid-market private equity firms in German-speaking Europe, on the staged exit from of its 20% minority stake in Stadler Rail, by selling to Peter Spuhler, CEO and majority shareholder in Stadler Rail

Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals

Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company

Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company

Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment

Advised CVC Capital Partners on the divestiture of Adisseo via the sale of Drakkar Holdings SA to China National BlueStar, a subsidiary of state-owned diversified chemicals company China National Chemical Corporation. Adisseo is a leading player in the animal nutrition market